- Home
- KD vs DNLI Comparison
KD vs DNLI Comparison
Compare KD & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KD | DNLI |
|---|---|---|
| Founded | 2020 | 2013 |
| Country | United States | United States |
| Employees | 80000 | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.0B |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | KD | DNLI |
|---|---|---|
| Price | $11.28 | $21.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 14 |
| Target Price | $25.92 | ★ $34.33 |
| AVG Volume (30 Days) | ★ 3.6M | 1.7M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.85 | N/A |
| Revenue | ★ $15,092,000,000.00 | N/A |
| Revenue This Year | $3.73 | N/A |
| Revenue Next Year | $0.08 | $408.85 |
| P/E Ratio | $13.24 | ★ N/A |
| Revenue Growth | ★ 0.23 | N/A |
| 52 Week Low | $10.10 | $12.58 |
| 52 Week High | $43.74 | $23.77 |
Technical Indicators
Market Signals| Indicator | KD | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 36.45 | 62.05 |
| Support Level | $11.11 | $17.77 |
| Resistance Level | $13.81 | $22.07 |
| Average True Range (ATR) | 0.52 | 1.02 |
| MACD | -0.05 | 0.17 |
| Stochastic Oscillator | 10.84 | 99.15 |
Price Performance
Historical ComparisonAbout KD Kyndryl Holdings Inc.
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives. The company's reportable segments consist of the following: Principal Markets which represents its operations in operations in Australia / New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, and the United Kingdom / Ireland, United States, Japan, and Strategic Markets. It derives maximum revenue from the United States.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.